XBiotech IncNASDAQ:XBIT
- LAST PRICE3.4500
- TODAY'S CHANGE (%)0.0800 (2.3739%)
- Bid / Lots3.2200/ 5
- Ask / Lots3.5500/ 5
- Open / Previous Close3.4500 / 3.3700
- Day Range
- 52 Week Range
- Volume34,456
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XBIT |
|---|---|---|
| 09:32 ET | 1000 | 3.45 |
| 10:42 ET | 9900 | 3.4599 |
| 10:44 ET | 600 | 3.4577 |
| 10:46 ET | 125 | 3.4546 |
| 10:53 ET | 300 | 3.455 |
| 11:04 ET | 1955 | 3.4456 |
| 11:06 ET | 1998 | 3.4237 |
| 11:29 ET | 100 | 3.45 |
| 11:36 ET | 419 | 3.45 |
| 11:42 ET | 434 | 3.435 |
| 01:21 ET | 235 | 3.44 |
| 01:42 ET | 451 | 3.44 |
| 02:15 ET | 6415 | 3.47 |
| 02:24 ET | 100 | 3.49 |
| 02:27 ET | 200 | 3.451 |
| 02:40 ET | 100 | 3.475 |
| 02:51 ET | 100 | 3.485 |
| 02:56 ET | 100 | 3.485 |
| 03:20 ET | 200 | 3.485 |
| 03:21 ET | 1000 | 3.4885 |
| 03:27 ET | 100 | 3.485 |
| 03:30 ET | 100 | 3.485 |
| 03:50 ET | 200 | 3.485 |
| 03:56 ET | 300 | 3.485 |
| 03:59 ET | 725 | 3.45 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
XBiotech Inc | 105.0M | -3.2x | --- |
Sol Gel Technologies Ltd | 99.7M | -6.0x | --- |
Matinas BioPharma Holdings Inc | 102.1M | -4.9x | --- |
Capricor Therapeutics Inc | 106.6M | -3.6x | --- |
MediciNova Inc | 105.9M | -7.5x | --- |
X4 Pharmaceuticals Inc | 106.3M | -0.5x | --- |
Company Information
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases. The Company is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. Its True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. The Company has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. The Company is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure.
Contact Information
- Headquarters
- 5217 WINNEBAGO LANEAUSTIN, TX, United States 78744
- Phone
- 512-386-2900
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- John Simard
- Principal Financial Officer, Director of Finance, Principal Accounting Officer
- Angela Hu
- Chief Scientific Officer
- Sushma Shivaswamy
- Lead Independent Director
- Jan-Paul Waldin
- Independent Director
- Peter Libby
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $105.0M |
|---|---|
Revenue (TTM) | $4.0M |
Shares Outstanding | 30.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-1.08 |
Book Value | $7.90 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 26.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -860.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
